1. The latest news: Biogen not leaving amyloid beta theory yet; new clinical trial starting — Digital health just had a record year — Conatus and Novartis suffer another NASH flop -- See more on our front page news

    Plus NEW BOARDS added recently
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

Xiidra days are numbered...

Discussion in 'Shire' started by anonymous, Mar 16, 2019 at 10:46 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    you know you have 2 months to get your sh*t together.
     
  2. anonymous

    anonymous Guest

    So Glad I left this shithole. It was nice icing on the cake to get my q3 and q4 bonus after leaving, thanks Shire!!!
     
  3. anonymous

    anonymous Guest

    rumor is Alcon. No backfills and everyone is talking about adding X to the mix
     
  4. anonymous

    anonymous Guest

    yes I've heard similarly
     
  5. anonymous

    anonymous Guest

    It's actually Novartis and they don't have any interest. Alcon was spun off.
     
  6. anonymous

    anonymous Guest

    Me too!
     
  7. anonymous

    anonymous Guest

    a bunch of fools that stayed on and bought M and J’s lines about a spin off. Can’t stop the giggling. Spin off of their own company!!!! LMFAO
     
  8. anonymous

    anonymous Guest

    I do not recall them once speaking about a spin off. Maybe people stayed because they are happy. Go have fun wherever you went. I hope it works out for you. Most likely if you couldnt make it selling Xiidra youll be looking for a job next year anyway.
     
  9. anonymous

    anonymous Guest

    We have stay because there is zero sales pressure and no stress with this job. Nobody enjoys selling Xiidra. We are paid very well to work 10-15 hrs per week. We all know the end is near. JS and MC do sell that “everything will work out” and it is “business as usual”. We all know they are FOS. I agree that it is our choice to stay or leave. We’ll all be leaving soon as we will be sold off.
     
  10. anonymous

    anonymous Guest

    They’ve spoken multiple times about a spin off and even possibly being taken over by a venture capitalist group. Either you are stupid, not listening, or both!
     
  11. anonymous

    anonymous Guest

    Stop making stuff up you rubblerouser
     
  12. anonymous

    anonymous Guest

    The Alcon spinoff will be finalized at the end of April- that is public information. The “new Alcon” will have vision care, ie daily contact lenses, the Systane line, and the iLux machine that competes against Lipiflow. Gee, what’s the one missing piece for their newly developed Dry Eye Business Unit?
     
  13. anonymous

    anonymous Guest

    This would be a perfect match for us!!
     
  14. anonymous

    anonymous Guest

    Wouldnt mind selling that i lux machine. Definitely an upgrade over blephx not sure about lipiow though. Im sure the cost willbe less with ilux.
     
  15. anonymous

    anonymous Guest

    ‘Public Information”? Please attach link where the OBU will be spun off “at the end of April”!
     
  16. anonymous

    anonymous Guest

    this post is delicious. I do remember talks of the spinoff with VH and another manager drinking the kool aid in the East. CH in the Carolinas. This is all so good with wine
     
  17. anonymous

    anonymous Guest

    hello...is there anyone there..? This is about Alcon....
     
  18. anonymous

    anonymous Guest

    I've heard the same. what person in their right mind would apply for a job here? clearly not a good sales rep.
     
  19. anonymous

    anonymous Guest

    Novartis is keeping all pharmaceutical products and Alcon will be operating separately with all NON pharma products. So, if Xiidra and or the OBU is purchased it would be a Novartis product. Not Alcon.
     
  20. anonymous

    anonymous Guest

    If that's your gig. I was BORED. Everyone I know is bored. Slowly whittling away chances of other eyecare positions.
     

play:inline;">